Kenya’s pharmaceutical supply chain continues to align with international Good Distribution Practice (GDP) and Pharmacy and Poisons Board (PPB) expectations. In 2026, facilities are placing greater emphasis on documented temperature control, batch traceability, and qualified storage — not only for vaccines but for a wider range of cold-chain medicines.
What GDP means for your facility
GDP covers the full distribution chain: procurement, storage, transport, and documentation. For hospitals and pharmacies, this translates into clear expectations for suppliers:
- Validated cold-chain packaging and monitoring devices on delivery
- Batch numbers, expiry dates, and certificates of analysis available on request
- Recall readiness and adverse-event reporting pathways
- Segregation of quarantined, approved, and rejected stock at the depot level
Cold-chain beyond vaccines
While immunisation programmes drove early investment in 2–8 °C capacity, biologics, certain insulins, and select oncology support products now require the same discipline. Facilities should audit whether their distributor can provide continuous temperature logs and deviation investigations when excursions occur.
Practical steps for procurement teams
- Include GDP and cold-chain clauses in supply agreements and tenders.
- Request standard operating procedures (SOPs) for storage and transport.
- Schedule joint stock reconciliations for high-value and cold-chain lines.
- Train receiving staff on immediate inspection and data logger download.
Consolata maintains GDP-aligned processes for pharmaceutical distribution nationwide. Contact our team for compliance documentation or a cold-chain capability review for your institution.